Recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment NCT06589804 Conditions Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +38 more Locations University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States Fremont - Rideout Cancer Center — Marysville, California, United States VA Palo Alto Health Care System — Palo Alto, California, United States UCHealth Memorial Hospital Central — Colorado Springs, Colorado, United States View all 192 locations View more locations Show fewer locations Loading locations... View Trial Details
Recruiting IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 Conditions Adnexal Diseases, Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, +71 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
Recruiting Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma NCT06211335 Conditions Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +8 more Locations University of California Davis Comprehensive Cancer Center — Sacramento, California, United States University of Colorado Denver | Anschutz Medical Campus — Aurora, Colorado, United States View Trial Details
